Use of ST250 to Reconstruct Lateral Tongue Defects

To assess the use of SupraThel 250 for mucosal reconstruction in the Head & Neck region. The membrane is applied to reconstruct lateral tongue defects . healing of the mucosa and regaining of normal tongue movement and speech are assessed postoperatively.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tongue Neoplasms Head and Neck Neoplasms Mouth Diseases Mouth Neoplasms Neoplasms Neoplasms by Site Stomatognathic Diseases Tongue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

MarienHospital

Stuttgart, Baden-Wurttemberg, Germany

About this study

Lateral tongue defects are usually treated using radial fore-arm free grafts which require a prolonged hospital stay with higher morbidity rates. It also entails the need of multiple rehabilitation and remodeling porcdures of the transplnted flap to enable intelligible speech and tongue function.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

lateral tunge defects (postoncologic resection)

Exclusion criteria

radio / chemotherapy
pregnant/ breastfeeding women

Treatment and study plan

Primary outcomes

Pain score

Time frame: 5 days

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Collaborators

Marienhospital Stuttgart

Registry information

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2025
First posted: May 23, 2025
Registry last updated: May 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed